Single alloantibodies were found in 76.8% patients, two alloantibodies were found in 17.9% and three or more in 5.3% of alloimmunized patients. in donors were anti-Lea, anti-Mia, anti-Leb, anti-M and anti-D. Conclusions: One of the most GDC-0032 (Taselisib) generally recognized alloantibodies in the Thai populace GDC-0032 (Taselisib) analyzed was anti-Mia suggesting that Mia positive reddish cells should routinely be included in antibody screening and identification in this populace. For antibody screening and identification, CAT method detected immune and warm alloantibody (ies) more frequently than that associated with standard tube techniques. strong class=”kwd-title” Keywords: Alloantibody frequency in thais, antibody identification, antibody screen, column agglutination technology, standard tube method Introduction Sensitization to reddish cell antigens may result from previous transfusions, pregnancy, transplantation or injection of immunogenic material. Blood group antibodies may also be naturally occurring. The frequency of alloantibodies varies depending on populace demographics and the sensitivity of detection techniques used. The southern Thai populace have different ethnic origins compared to other regions of Thailand. The majority of the southern populace is local Thais living in the upper South. Thai people living in lower southern Thailand near the border with Malaysia often may have Malay ancestry. The aims of this study were to determine the specificity and compare the frequency of alloantibodies detected using column agglutination technology (CAT) and standard tube techniques using normal saline suspended reddish cells in blood donors and GDC-0032 (Taselisib) previously transfused patients. Settings and Design Antibody screening and identification All patient’s blood group, antibody screen, antibody identification and cross-match records from your Blood Lender and Transfusion Medicine Unit, Songklanagarind University Hospital for the 1 year period of 1st January- 31st December 2006 and the 2 2 IL3RA year period of 1st January 2008-31st December 2009 were examined. Similarly blood donor laboratory records from 1st January-31st December 2006 and during 1st January 2008-31st December 2009 were examined. Prior to 2007 standard tube techniques using reddish cells suspended in normal saline were routinely utilized for antibody screening using two group O screening cells. Antigen protection included D, C, E, c, e, Fya, Fyb, Jka, Jkb, Lea, Leb, Mia, M, N, K, k, S, s, P1, Lua, Lub and Dia. Antibody identification was performed using a panel of eleven group O cells. Antibody screening and antibody identification panel cells were provided by the Thai National Blood Centre (NBC) of Thai Red Cross. The indirect antiglobulin tube technique was utilized for antibody screening. Antibody identification techniques included a room heat incubation phase, a 37C phase and indirect antiglobulin phase using polyspecific anti-human globulin (made up of anti-IgM, anti-IgG and anti-C3d which was manufactured by the Thai NBC). Column agglutination technology was launched into routine laboratory techniques for ABO and RhD grouping, antibody screening and antibody identification in 2008. All blood grouping and antibody screening was performed using an automated platform (AutoVue Innova?, Ortho Clinical Diagnostics, USA). ABO and RhD groups were tested using BioVue ABO-Rh/Reverse Grouping cassettes (Ortho BioVue? System, Ortho Clinical Diagnostics, USA). Standard reverse grouping cells were A1 and B cells (0.8% Affirmagen?, Ortho-Clinical Diagnostics, USA). Antibody screening was performed using BioVue Poly cassettes (Ortho BioVue? System). Three group O screening cells were used in the antibody screen. 2 screening cells were obtained from Ortho Clinical Diagnostic (0.8% Selectogen?, Ortho-Clinical Diagnostics, USA). Antigens covered included: D, C, E, c, e, Fya, Fyb, Jka, Jkb, Lea, Leb, M, K, k, S, s, N, P1, Lub, Kpb, and Jsb. In addition a third group O screening cell which was Mia and Dia positive, was provided by the Thai NBC. 0.8% cell suspensions of this screening cell were made in low.